PARIS – A 16-gene expression test that Genomic Health developed in collaboration with Pfizer was able to determine in a validation study which clinically high-risk, stage III kidney cancer patients would experience recurrence following surgery.
PARIS – A 16-gene expression test that Genomic Health developed in collaboration with Pfizer was able to determine in a validation study which clinically high-risk, stage III kidney cancer patients would experience recurrence following surgery.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.